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Structural alignment of the human androgen receptor
dimer was investigated by introducing steroid binding
domain mutations that cause partial or complete andro-
gen insensitivity into fusion proteins containing the
full-length androgen receptor or the steroid binding do-
main. Most of the mutants had unchanged apparent
equilibrium androgen binding affinity and increased
dissociation rates of [3H]methyltrienolone and required
increased dihydrotestosterone concentrations for tran-
scriptional activation. In a 2-hybrid protein interaction
assay in mammalian cells, the steroid binding domain
interacts with an NH2-terminal-DNA binding domain
fragment and with the full-length androgen receptor at
physiological androgen concentrations in a dose-
dependent manner. However, mutations at Val-889 and
Arg-752 disrupt the NH2-/carboxyl-terminal interaction
when introduced into the steroid binding domain frag-
ment but not when present in the full-length androgen
receptor. The N-C bimolecular interaction reduces the
dissociation rate of bound androgen and slows the deg-
radation rate of the carboxyl-terminal steroid binding
domain fragment. The results suggest that steroid bind-
ing domain residues Val-889 and Arg-752 are critical to
the NH2-/carboxyl-terminal interaction and that an in-
termolecular N-C interaction occurs during receptor
dimerization that results in an antiparallel arrange-
ment of androgen receptor monomers.
Steroid hormone receptor dimerization required for optimal
DNA binding (1–5) is mediated by the second zinc finger region
in the DNA binding domain (6) and by a carboxyl-terminal
region in the steroid binding domain (7–10). Some steroid re-
ceptors do not require steroid binding for dimerization (11–13)
or dimerize independent of DNA binding (5, 14–16). For the
androgen receptor (AR),1 binding to androgen response ele-
ment DNA requires androgen-dependent AR dimerization (17).
Recent evidence using a 2-hybrid protein interaction assay in
mammalian cells indicates that AR dimerization involves an
androgen-dependent interaction between the NH2-terminal
and carboxyl-terminal steroid binding domains (N-C interac-
tion) that is of sufficiently high affinity to occur bimolecularly,
independent of the AR DNA binding domain (18). Similar N-C
interactions in the estrogen receptor (ER) led to a parallel
dimerization model (19). An unresolved issue in the steroid
receptor field, therefore, is whether receptor dimerization has a
parallel or antiparallel orientation (20). In support of the par-
allel model, evidence was reported for ER dimerization through
direct hydrophobic interactions between steroid binding do-
mains (21–23). An Src homology 2 domain-type interaction
with phosphorylated tyrosine 537 in the ER steroid binding
domain may be involved in ER dimerization although dimer
orientation was not addressed (24). Another report suggested
dimerization occurs in a head-to-toe, antiparallel arrangement
(25). In support of the antiparallel model, the glucocorticoid
receptor NH2-terminal domain was implicated in dimerization
(26). For the thyroid hormone and vitamin D receptors, the
DNA binding domain has rotational flexibility relative to the
dimerization interface in the steroid binding domain, allowing
a 180° change in conformation (27). The vitamin D receptor
may form a symmetrical, head-to-tail, antiparallel dimer
through the DNA binding domain but is influenced by the
steroid binding domain dimerization interface (28).
Several lines of evidence argue against a parallel dimer for
androgen-activated AR. First, no interaction is observed be-
tween the AR steroid binding domains in the 2-hybrid protein
interaction assay in the presence or absence of androgen (18).
Second, the N-C interaction is of sufficiently high affinity to
promote a bimolecular interaction. Third, the steroid specificity
of N-C-mediated dimerization parallels that of full-length AR.
Fourth, antiparallel interactions between N-C regions of AR
NH2- and carboxyl-terminal fragments promote high affinity
DNA binding. In the present report, evidence for an intermo-
lecular N-C interaction in an antiparallel AR dimer was ob-
tained by the introduction of single base mutations into the AR
steroid binding domain that cause partial or complete andro-
gen insensitivity without altering the apparent equilibrium
androgen binding constant and by examining the influence of
the NH2-terminal domain on androgen dissociation rates and
protein turnover.
EXPERIMENTAL PROCEDURES
Expression Plasmids—Eukaryotic expression vectors pGALO, con-
taining the DNA binding domain of the Saccharomyces cerevisiae GAL4
protein (amino acid residues 1–147), and pNLVP, coding for the tran-
scriptional activation domain of the herpes simplex virus VP16 protein
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(residues 411–456), were previously described (29) and kindly provided
by Gordon Tomaselli, Johns Hopkins University. These vectors were
used to construct the full-length AR vector pNLVP-hAR (designated
here as pVPAR) and the carboxyl terminal AR fragment vector
pGALD-H (containing AR amino acid residues 624–919) (18). pVPAR1–
660 contains the VP16 transactivation domain 59 of human AR residues
1–660, including the NH2-terminal, DNA binding, and part of the hinge
regions, and was constructed from the full-length vector by deleting the
carboxyl terminal portion using TthIII/XbaI followed by ligation of the
filled ends. Androgen insensitivity mutations V889M and V866M were
introduced into pGALD-H and pVPAR by polymerase chain reaction
(PCR) amplification of pCMVhAR-V889M (30, 31) and pCMVhAR-
V866M (32). Amplified fragments were cloned into pGALO at NdeI/
XbaI, in the case of the D-H fragment, or into VPAR using CspXI/XbaI.
Bi-directional PCR mutagenesis was used to construct pGALD-H-
R752Q, which was used to construct pCMVhAR-R752Q at the TthIII/
XbaI restriction sites and pVPAR-R752Q at BstEII/XbaI. pCMVhAR-
Y763C was constructed by PCR mutagenesis changing TAC codon 763
to TGC. PCR fragments were digested with HincII/XbaI, and a triple
ligation reaction was performed with the NdeI/HincII fragment of pV-
PAR or pGALD-H. pCMVhAR-Y763C was constructed in the HindIII/
XbaI fragment from pGALD-H-Y763C. The sequence of all PCR-ampli-
fied regions was verified.
Cell Culture, DNA Transfections, Binding Assays, and Immuno-
blots—Chinese hamster ovary (CHO) cells were maintained in alpha
minimum essential medium containing 10% bovine calf serum, 20 mM
Hepes, pH 7.2, penicillin, and streptomycin, plated at 4.5 3 105 cells/
6-cm dish, and transfected with 1–2 mg of expression vector DNA and 5
mg of G5E1bLuc reporter vector using DEAE-dextran as described (18).
After addition of increasing concentrations of DHT and incubation for
24 h, cells were harvested and assayed for luciferase activity as
described (18).
Apparent equilibrium binding affinity was determined in whole cell
binding assays as described (33). Monkey kidney COS-1 cells were
plated at 3.5 3 105 cells/well of 6-well culture plates and transfected
using DEAE-dextran with 3 mg of DNA for AR fragments containing the
steroid binding domain and 1–2 mg for full-length AR. After 48 h, cells
were incubated with 0.25–5 nM [3H]R1881 for 2 h at 37 °C. Dissociation
rate constants were determined by labeling with 5 nM [3H]R1881 for 2 h
at 37 °C followed by the addition of a 10,000 molar excess of unlabeled
R1881. Cells were washed twice with phosphate-buffered saline and
harvested in 0.5 ml of 2% SDS, 10% glycerol, and 10 mM Tris, pH 6.8.
Specific binding was determined from the difference in radioactivity in
the presence and absence of a 100-fold molar excess unlabeled R1881 as
described previously (31).
Protein expression levels were compared by immunoblot analysis of
wild-type and mutant full-length AR and partial AR fusion proteins
expressed in COS-1 cells and analyzed in 9 or 12% acrylamide SDS gels
using AR52 antipeptide antibody (34) or the GAL4 DNA binding do-
main antibody (Santa Cruz Biotechnology). Secondary antibody was
anti-rabbit IgG (Promega).
Degradation rates were determined in COS-1 cells (1 3 106/10-cm
dish) transiently transfected using DEAE-dextran with 4 mg of AR507–
919 plus either 8 mg of parent expression plasmid pCMV5 or 8 mg of
AR1–660. Cells were maintained in 10% serum and, after 48 h, were
incubated in serum-free, methionine-free media as described previously
(31) except with 100 mCi [35S]L-methionine/L-cysteine PRO-MIX in vitro
cell labeling mix (1000 Ci/mmol) (Amersham Life Science, Inc.). After 30
min of labeling, cells were washed, placed in serum-free media with or
without 100 nM DHT at 37 °C, and harvested at time intervals up to 7 h.
Cells were harvested in RIPA buffer (1% Triton X-100, 1% deoxycholate,
0.1% SDS, 0.15 M NaCl, 5 mM EDTA, and 50 mM Tris, pH 7.4), and cell
extracts were incubated with AR52 anti-peptide antibody and Pan-
sorbin and processed for polyacrylamide gel analysis as described
previously (31).
RESULTS
Steroid Binding Domain Amino Acid Residues Involved in
the N-C Interaction and Polarity of AR Dimerization—The po-
larity of AR dimerization was investigated by introducing nat-
urally occurring mutations that cause partial or severe forms of
FIG. 1. Immunoblots of partial and full-length AR with wild-
type or androgen insensitivity mutation sequence expressed
alone or as fusion proteins. COS-1 cells were transfected using
DEAE-dextran as described under “Experimental Procedures” with 10
mg of DNA/1.2 3 106 cells/10-cm dish. Forty-eight h after transfection
and in the absence of androgen, COS cells were harvested in SDS
containing buffer and analyzed in 12% (A) or 9% (B, C) acrylamide gels.
A, GALD-H expression vectors contain the S. cerevisiae GAL4 DNA
binding domain residues 1–147 (GAL DBD) and AR steroid binding
domain residues 624–919 (coded by exons D-H) with the indicated
androgen insensitivity mutations. Expressed GALD-H fusion proteins
(50 kDa apparent Mr; 49 kDa calculated; 50 ml) were detected using a
rabbit anti-GAL DNA binding domain antibody (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA). The GAL4 DNA binding domain (19 kDa
apparent Mr; 16.3 kDa calculated) is evident in lane 7 from the ex-
pressed parent vector, pGALO, that lacks AR sequence. B, VPAR ex-
pression vectors contain the herpes simplex virus VP16 transactivation
domain residues 411–456 and full-length AR residues 1–919 with the
indicated mutations. VPAR fusion proteins (120 and 126 kDa apparent
Mr; 112 kDa calculated; 50 ml) were detected using antipeptide AR52
IgG previously described (34). Expression of the parent vector pVP16
without AR sequence is shown in lane 7. C, pCMVhAR expression
vectors contain full-length AR residues 1–919 with the indicated mu-
tations. Full-length AR (113 kDa apparent Mr; 102 kDa calculated) was
detected using AR52 IgG. Expression of the parent vector pCMV5
lacking AR sequence is shown in lane 7. Shown are extracts (40 ml) from
cells expressing parent vectors with wild-type AR sequence (lane 1, WT)
or with the following androgen insensitivity AR mutations: V889M
(lane 2, VM889), V866M (lane 3, VM866), R752Q (lane 4, RQ752),
Y763C (lane 5, YC763), Y763H (lane 6, YH763), and the parent vectors
lacking AR sequence (lane 7).
TABLE I
Equilibrium dissociation constant, Kd (nM)
Apparent equilibrium binding constants and standard deviations
were determined in COS cells using increasing [3H]R1881 as described
under “Experimental Procedures.”
Full-length AR507–919 GALD-H AIS gradea
Wildtype 0.64 6 0.32 0.25 6 0.06 0.12 6 0.04 —
V889M 0.79 6 0.35 0.41 6 0.26 0.19 6 0.06 6
R752Q 1.2 6 0.32 1.0 6 0.70 0.55 6 0.11 7
Y763C 0.84 6 0.34 0.54 6 0.27 0.29 6 0.30 2/3b
Y763H 1.1 6 0.45 0.23 6 0.03 0.32 6 0.13 7
V866M 2.9 6 0.65 1.1 6 0.50 0.35 6 0.10 6
a AIS grades are as previously reported (35).
b AIS grade 2/3 was associated with shortening of the Gln repeat in
the NH2-terminal region to 12 residues (38) (wild-type 23 Gln 6 2).
TABLE II
Dissociation half-time of [3H]R1881 (min)
Dissociation half-times were determined at 37 °C as described under
“Experimental Procedures” with averages and standard deviation from
at least three independent experiments.
Full-length AR AR507–919 GALD-H
Wildtype 150 6 34 39 6 2 30 6 6
V889M 18 6 2 4 6 1 6 6 3
R752Q 12 6 2 6 6 2 13 6 3
Y763C 52 6 5 21 6 6 14 6 1
Y763H 35 6 4 NDa 10 6 4
V866M 36 6 5 20 6 2 20 6 4
a ND, not determined.
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androgen insensitivity. The mutations were constructed by
mutagenesis of GALD-H, which contains human AR steroid
binding domain residues 624–919 (coded by exons D-H) fused
to the carboxyl-terminal end of GAL4 DNA binding domain
residues 1–147, or into VPAR, which contains full-length hu-
man AR residues 1–919 fused to the carboxyl-terminal end of
VP16 transactivation domain residues 411–456. AR mutations
that result in partial or complete androgen insensitivity either
do not significantly alter (V889M, R752Q, Y763C, Y763H) or
decrease (V866M) the apparent equilibrium binding affinity for
the synthetic androgen, [3H]R1881 (Table I). Equilibrium an-
drogen binding affinities of the full-length AR mutants shift
toward higher affinities when the NH2-terminal region is de-
leted in AR507–919 and in the GALD-H fusion proteins (Table
I). However all of the full-length androgen insensitivity mu-
tants have increased rates of [3H]R1881 dissociation (Table II)
relative to wild-type AR, suggesting correspondingly increased
association rates in mutants with equilibrium binding con-
stants similar to that of wild-type AR. Deletion of the NH2-
terminal domain results in increased dissociation rates of
[3H]R1881 (Table II) for all mutants as previously reported for
wild-type AR (18). Expression levels of the wild-type and mu-
tants are similar for the partial AR fusion proteins in GALD-H
(Fig. 1A), for full-length ARs expressed as fusion proteins with
the VP16 transactivation domain (Fig. 1B), or full-length AR
(Fig. 1C) as determined from immunoblots of extracts from
transiently transfected COS-1 cells. However, protein expres-
sion from pCMV5 is at least 2-fold higher than from pVP16.
When introduced into the mammalian expression vector pCM-
VhAR and assayed with the MMTV-luciferase reporter vector,
most of the androgen insensitivity mutants require DHT con-
centrations above the physiological range to promote full tran-
scriptional activation (Fig. 2).
GALD-H interacts with VPAR1–660 (AR NH2-terminal, and
DNA binding domain residues 1–660 fused carboxyl terminal
to the VP16 transactivation domain) in the presence of DHT in
a concentration-dependent manner. Luciferase activity of 3–16
fold becomes detectable at 0.01 nM DHT, with full activation
between 22–31 fold at 1–10 nM DHT (Figs. 3A, 4A, 5A, and 6A,
left). VP-full-length AR (VPAR) interacts with GALD-H in a
similar concentration dependent manner with DHT, with up to
an 11-fold increase in luciferase activity at 0.01 nM DHT and
full activation of 12–34 fold at 1–5 nM DHT (Figs. 3B, 4B, 5B,
and 6B, left). These results indicate that the N-C interaction
occurs as a bimolecular reaction when one monomer is either
full-length AR or the NH2-terminal and DNA binding regions
FIG. 2. Androgen-induced transcriptional activation of the MMTV promoter-luciferase reporter vector by full-length wild-type AR
and mutant ARs that cause partial or complete androgen insensitivity. Monkey kidney CV1 cells (3.5 3 105/6-cm dish) were transiently
transfected with 100 ng of pCMVhAR with wild-type sequence (AR) or with the indicated human androgen insensitivity mutations and the
testicular feminized androgen-resistant rat mutation (R734Q) in pCMVrAR and 5 mg of MMTV-luciferase reporter vector using calcium phosphate
precipitation as described previously (47). Cells were incubated for 30 h with increasing concentrations of DHT from 0.001 to 100 nM as indicated,
and optical light units were determined using an automatic luminometer. Shown is a representative experiment of at least three independent
determinations.
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and the other monomer contains only the AR steroid binding
domain. The similar dose-dependent N-C interaction between
the steroid binding domain and either full-length AR or the
NH2-terminal fragment supports the antiparallel dimer model.
Self dimerization of VPAR apparently does not interfere with
its interaction with GALD-H.
V889M—V889M results from a GTG 3 ATG mutation in
exon H that causes grade 6 androgen insensitivity (female
external phenotype with pubic hair in a 46XY genetic male)
(30, 35) without altering equilibrium androgen binding (30) but
increasing the dissociation rate of [3H]R1881 (31) from the
full-length mutant AR (Table II). The dissociation rate of
[3H]R1881 increases about 4-fold further with deletion of the
NH2-terminal region in AR507–919 (DNA and steroid binding
domains) (Table II), suggesting that, at the high androgen
concentration (50 mM unlabeled R1881) used in the dissociation
experiment, the NH2-terminal region slows androgen dissocia-
tion from V889M to an extent similar to wild-type AR. The
5–10-fold faster androgen dissociation rate from AR507–919-
V889M and GALD-H-V889M relative to these wild-type AR
fragments suggests, in addition, that increased androgen dis-
sociation is an inherent defect of the V889M mutation in the
steroid binding domain (Table II).
The interaction between GALD-H-V889M and VPAR1–660
occurs only at DHT concentrations of 5 nM or greater, about 500
times the concentration required for the wild-type GALD-H
and VPAR1–660 interaction, and increases to only 12–16-fold,
up to 1 mM DHT (Fig. 3A, right). On the other hand, reactivity
of VPAR-V889M with GALD-H was similar to wild-type VPAR
(Fig. 3B, middle), and little interaction is observed between
VPAR and GALD-H-V889M except at high DHT concentrations
(Fig. 3B, right). The results support an intermolecular N-C
interaction where GALD-H interacts with the NH2-terminal
region of VPAR-V889M, which is unaffected by the V889M
steroid binding mutation in VPAR-V889M. The similar dose
response in interaction between GALD-H with VPAR or VPAR-
FIG. 3. 2-hybrid protein interaction
assay between AR NH2- and carboxyl-
terminal domains. The 2-hybrid assay
was performed in CHO cells as described
previously (18). A, VPAR1–660, coding for
AR NH2-terminal residues 1–660 and the
VP16 activation domain, was cotrans-
fected with GALD-H, coding for wild-type
AR steroid binding domain residues 624–
919 (left) or with GALD-H-V889M (right)
(codon 889 GTG3ATG). B, VPAR, coding
for wild-type full-length AR residues
1–919 (left) or VPAR-V889M (middle) ex-
pressed as fusion proteins with the VP16
activation domain were transfected with
GALD-H with wild-type sequence, or
VPAR was transfected with GALD-H-
V889M (right). DNA (1 mg of each expres-
sion plasmid) was transfected with 5 mg of
G5E1bLuc reporter plasmid using DEAE-
dextran and incubated for 30 h with 0.01
nM to 1 mM DHT as indicated. Luciferase
activity is shown as optical light units and
is representative of at least three inde-
pendent experiments. Schematic dia-
grams of the constructs are shown where
the shaded area represents the AR DNA
binding domain, and 3 represents the
V889M mutation. Fold induction relative
to luciferase activity in the absence of
DHT is indicated above the bars.
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V889M suggests that low physiological DHT concentrations are
sufficient to promote this bimolecular reaction and may reflect
the retained high androgen binding affinity of V889M (Table I).
R752Q—Androgen insensitivity in the testicular feminized
(Tfm) rat results from a single base mutation CGG 3 CAG in
exon E of the AR steroid binding domain changing Arg 734 to
Gln (33). This mutation lowers androgen binding capacity with
only slightly lower apparent equilibrium binding affinity (Ta-
ble I) (33). The Tfm rat AR mutation occurs in human AR (Arg
752 to Gln, CGA 3 CAA) in two unrelated families with com-
plete androgen insensitivity; however, in these cases, androgen
binding activity was not reported (36, 37). The R752Q human
AR mutant and the R734Q Tfm rat mutant (33) require at least
10,000-fold higher DHT concentrations than wild-type AR for
transcriptional activation of a mouse mammary tumor virus
reporter vector (Fig. 2). Like V889M, the apparent binding
affinity of R752Q for [3H]R1881 is similar to that of wild-type
AR (Table I), and dissociation of [3H]R1881 is at least 11 times
faster in full-length AR and increases or is similar in the
truncated fragments containing the DNA and steroid binding
domains (AR507–919) or the steroid binding domain fusion
protein in GALD-H (Table II). These results suggest that the
R752Q binding defect is inherent to the steroid binding do-
main. This previously unrecognized rapid androgen dissocia-
tion kinetics from human AR R752Q and Tfm rat AR R734Q,
combined with the low binding capacity, likely account for the
inability of other laboratories (36, 37) to detect androgen binding
using conventional radiolabeling binding assays of endogenous
AR in fibroblasts from affected individuals with the R752Q mu-
tation and for the 10% binding levels relative to wild-type sib-
lings resulting from the synonymous R734Q mutation in the Tfm
rat (33).
FIG. 4. 2-hybrid protein interaction
assay of R752Q. The 2-hybrid assay was
performed as described (18). The R734Q
AR mutation of the testicular feminized
rat (33) was introduced into pCMVhAR at
codon 752 CGA3CAA of human AR. A,
VPAR1–660 coding for AR NH2-terminal
residues 1–660 fused to the VP16 trans-
activation domain was transfected with
GALD-H (left) or GALD-H-R752Q (right).
B, VPAR (left) or VPAR-R752Q (middle)
was transfected with GALD-H, or VPAR
was transfected with GALD-H-R752Q
(right). DNA (1 mg of each plasmid) was
cotransfected with 5 mg of G5E1bLuc re-
porter plasmid using DEAE-dextran and
incubated for 30 h with 0.01 nM to 1 mM
DHT as indicated. Luciferase activity
shown as optical light units is represent-
ative of at least three independent exper-
iments. Schematic diagrams of the con-
structs are shown where the shaded area
represents the AR DNA binding domain,
and 3 represents the R752Q mutation.
Fold induction relative to luciferase activ-
ity without DHT is indicated above the
bars.
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In the 2-hybrid protein interaction assay, R752Q disrupts
the N-C interaction between VPAR1–660 and GALD-H-R752Q
(Fig. 4A, right) to an extent similar to that observed for V889M
(Fig. 3A), suggesting that Val-889 and Arg-752 are both critical
residues in the steroid binding domain for the N-C interaction.
Also like V889M, the interaction between VPAR-R752Q and
GALD-H is similar to that of wild-type VPAR (Fig. 4B, left and
middle), and GALD-H-R752Q fails to interact with VPAR at
physiological androgen concentrations (Fig. 4B, right), support-
ing the antiparallel N-C dimer orientation. In both cases, re-
tention of high affinity binding with rapid binding and disso-
ciation kinetics suggests that perturbations around the
androgen binding pocket are critical to the N-C interaction.
Y763C—Tyr at 763 in exon E changes to Cys (TAC 3 TGC)
in a family with partial androgen insensitivity (grade 2/3, male
phenotype with hypospadias and virilization at puberty) (38)
and to His (TAC3 CAC) in an unrelated family with complete
androgen insensitivity (35). The Y763C mutation (reported pre-
viously as Y761C) occurred together with shortening of the
NH2-terminal Gln repeat from an average length of 22 residues
to 12 residues (38). Y763C is reported to increase the androgen
dissociation rate 2- to 3-fold with a slight increase in apparent
equilibrium binding affinity (Kd) (38). When recreated in full-
length AR, we observe a similar increase in the dissociation
rate of [3H]R1881 from Y763C with the apparent equilibrium
binding affinity indistinguishable from wild-type AR (Tables I
and II). The 2-hybrid protein interaction assay results indicate
only a slight decrease in transcriptional activity (Fig. 5), sug-
gesting that Tyr-763 is not critical for the N-C interaction. This
conclusion is supported by 2-hybrid results with Y763H (data
not shown). Y763H had similar equilibrium binding but 4-fold
faster dissociation kinetics of [3H]R1881 relative to wild-type
FIG. 5. 2-hybrid protein interaction
assay of Y763C. A, VPAR1–660 cotrans-
fected with GALD-H (left) or GALD-H-
Y763C (TAC3TGC) (right). B, VPAR
(left) or VPAR-Y763C (middle) was co-
transfected with GALD-H, or VPAR was
cotransfected with GALD-H-Y763C
(right). DNA (1 mg) was cotransfected
with 5 mg of G5E1bLuc reporter plasmid
using DEAE-dextran and incubated for
30 h with DHT as indicated. Luciferase
activity shown as optical light units is
representative of three independent ex-
periments. Schematic diagrams of the
constructs are shown where the shaded
area represents the AR DNA binding do-
main, and 3 represents the Y763C muta-
tion. Fold induction relative to luciferase
activity without DHT is indicated above
the bars.
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AR (Tables I and II) and causes more severe androgen
insensitivity.
V866M—Because the V889M and R752Q mutations shorten
the dissociation half-time of bound androgen 7–12-fold and
Y763C and Y763H only 2–4 fold, and whereas only the former
two were implicated in the N-C interaction, we investigated
androgen insensitivity mutant V866M to determine whether
increased androgen dissociation kinetics is associated with dis-
ruption of the N-C interaction. This GTG 3 ATG mutation in
exon G of the steroid binding domain causes complete androgen
insensitivity with a reported 4-fold reduction in androgen bind-
ing affinity (32). We also observe a 4–5-fold reduction in ap-
parent equilibrium binding affinity of [3H]R1881 and a 3–4-
fold increase in the dissociation rate of [3H]R1881 (Tables I and
II). GALD-H-V866M reacted with VPAR1–660 in a dose-de-
pendent manner with the dose response shifted to about 5-fold
higher DHT concentrations (Fig. 6A), a shift that can be ac-
counted for by the decreased apparent equilibrium androgen
binding affinity (Table I). Decreased sensitivity to DHT is also
observed in the interaction between GALD-H with VPAR-
V866M and between GALD-H-V866M and VPAR (Fig. 6B). The
parallel shift in dose response by the V866M mutant proteins
with the reduced binding affinity suggests that increased an-
drogen dissociation kinetics greater than 4-fold is associated
with disruption of the N-C interaction and that Val 866 is not
a critical residue for the N-C interaction.
Effect of the N-C Interaction on Androgen Dissociation—It
was shown previously that deletion of AR NH2-terminal resi-
dues 1–507 causes a 3-fold increase in the dissociation rate of
[3H]R1881 from the steroid binding domain with the apparent
FIG. 6. 2-hybrid protein interaction
assay of V866M. The V866M mutation
GTG3ATG was introduced into VPAR
and GALD-H as described under “Exper-
imental Procedures.” A,VPAR1–660 was
transfected with GALD-H (left) or GALD-
H-V866M (right). B, VPAR (left) or VPAR-
V866M (middle) was transfected with
GALD-H, or VPAR was transfected with
GALD-H-V866M (right). DNA (1 mg each)
was cotransfected with 5 mg of G5E1bLuc
reporter plasmid using DEAE-dextran
and incubated for 30 h with DHT as indi-
cated. Luciferase activity shown as opti-
cal light units is representative of at least
three independent experiments. Sche-
matic diagrams are shown, where the
shaded area represents the AR DNA bind-
ing domain, and 3 represents the V866M
mutation. Fold induction relative to lucif-
erase activity without DHT is indicated
above the bars.
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equilibrium binding affinity unchanged (31), indicating that
the association rate increases in parallel, and the NH2-termi-
nal region slows androgen association and dissociation kinet-
ics. It was not clear, however, whether slow androgen dissoci-
ation necessary for AR stabilization and transcriptional
activity (31, 39) is caused by an intramolecular N-C interaction
in the AR monomer or as part of the intermolecular N-C inter-
action in an antiparallel dimer. Coexpression of the DNA and
steroid binding domain fragment AR507–919 with a 3-fold
molar excess of transfected AR NH2-terminal fragment AR1–
660 DNA slowed the dissociation rate of [3H]R1881 from
AR507–919 about 2-fold (Fig. 7A). The dissociation rate of
[3H]R1881 from AR507–919 with the V889M mutation also
decreases by coexpression of AR1–660 in the presence of a high
concentration of unlabeled androgen in the dissociation exper-
iments (50 mM DHT). The dissociation rate of V889M remained,
however, about 10-fold faster than wild-type AR (Fig. 7). In this
bimolecular dimerization reaction, therefore, androgen dissoci-
ation rates slow toward that observed for wild-type AR, sug-
gesting that the N-C intermolecular interaction associated
with dimerization reduces the kinetics of androgen binding and
dissociation in the steroid binding domain pocket.
Effect of the N-C Interaction on AR Degradation—To inves-
tigate whether the antiparallel N-C interaction also mimics the
decrease in AR turnover observed with the transcriptionally
active full-length AR, the carboxyl-terminal AR507–919 vector
was coexpressed with a 2-fold molar excess of the NH2-terminal
AR1–660 expression vector or with the parent vector as a
control. Degradation half-time of the [35S]methionine/cysteine-
labeled AR507–919 was 2 h at 37 °C in the presence or absence
of 100 nM DHT, or in the presence of the NH2-terminal frag-
ment in the absence of DHT (Fig. 8). The degradation half-time
slowed to 4 h, however, in the presence of the NH2-terminal
fragment and 100 nM DHT (Fig. 8). The results suggest that the
antiparallel structural orientation in the bimolecular N-C in-
teraction of the AR fragments recapitulates the reduced andro-
gen dissociation and receptor turnover that occur in the tran-
scriptionally active full-length AR.
DISCUSSION
The N-C interaction observed for AR (18) and ER (19) has
raised at least two dimerization models for steroid receptors.
The parallel dimer model proposed for ER (19) implicates an
intramolecular N-C interaction within the ER monomer that
potentiates ER dimerization through conformational changes
and subsequent intermolecular interactions between the ste-
roid binding domains. The antiparallel dimer model proposed
for AR implicates an intermolecular N-C interaction between
monomers (18) in androgen-dependent AR dimerization and
specific DNA binding (17). Natural mutations in the AR steroid
binding domain that cause partial or complete androgen insen-
sitivity were introduced into AR fusion proteins to identify
steroid binding domain residues critical for the N-C interaction
and to investigate further the molecular alignment of the AR
dimer. Because naturally occurring mutations in the steroid
binding domain often decrease the apparent equilibrium an-
FIG. 7. Effect of the bimolecular N-C dimerization on [3H]R1881 dissociation. AR507–919 (2 mg) (44) containing the coding region for the
AR DNA and steroid binding domains with wild-type (A) or V889M (B) sequence in pCMV5 was transiently transfected in COS-1 cells alone (0)
or with a 3-fold molar excess (6 mg) pCMV5 either lacking AR sequence () or with AR1–660 in pCMV5 (M). AR1–660 contains the AR
NH2-terminal and DNA binding domain residues 1–660 (44). Full-length pCMVhAR (AR1–919) was included as a control (Œ). COS cells (3.5 3
105/6 cm dish) transfected using DEAE-dextran were labeled with 5 nM [3H]R1881 for 2 h at 37 °C. Dissociation was initiated by the addition of
10,000-fold molar excess of unlabeled R1881. Cells were washed twice with phosphate-buffered saline and harvested in SDS sample buffer, and
radioactivity was determined by scintillation counting. Nonspecific binding was determined by the addition of 100-fold excess unlabeled R1881 to
parallel samples at the initiation of the binding reaction.
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drogen binding affinity, it can be difficult to assess their role in
AR dimerization and DNA binding. More than 70 missense
mutations that cause partial or complete androgen insensitiv-
ity are located throughout the AR steroid binding domain (35).
The few that do not change the apparent androgen binding
affinity yet are associated with partial or complete androgen
insensitivity are particularly helpful in revealing additional
mechanisms involving the steroid binding domain.
A series of AR gene mutations that cause androgen insensi-
tivity without altering the apparent equilibrium androgen
binding affinity were introduced into full-length AR expressed
as a fusion protein with the VP16 transactivation domain or
into the AR steroid binding domain expressed as a fusion
protein with the GAL4 DNA binding domain to investigate
dimerization polarity. Two residues, Val-889 and Arg-752,
were identified as steroid binding domain residues critical for
the N-C interaction. Both V889M and R752Q mutations dis-
rupt the N-C interaction, suggesting that loss of function by
these mutations in individuals with androgen insensitivity re-
lates to ineffective N-C interaction at physiological androgen
concentrations. AR with either mutation is transcriptionally
active but requires androgen concentrations above the physio-
logical range to overcome the defect.
Steroid binding domain mutation V889M causes grade 6 (35)
androgen insensitivity (30). Its unaltered apparent equilibrium
binding constant with 8-fold increased dissociation and pre-
sumably increased association rates suggest that Val-889 is not
directly part of the steroid binding pocket but forms a struc-
tural barrier to androgen binding and dissociation. Val-889 is
situated 30 residues from the AR carboxyl terminus in a region
with sequence similarity to the region between helices 11 and
12 near the steroid binding pocket of the thyroid hormone b
receptor based on crystal structure analysis (40). Homo- and
heterodimerization interfaces of the thyroid hormone b recep-
tor (41) include helical regions 10 and 11 (40) corresponding to
human AR residues 855–883 preceding the V889M mutation.
The proximity of Val-889 to the steroid binding pocket suggests
this region undergoes conformational changes with androgen
binding. From the crystal structure of the human RXR-a ligand
binding domain, it was proposed that the region of helix 11
changes dramatically upon ligand binding (42). A region be-
tween residues 389–429 in the predicted helices 9 and 10 has
a role in establishing the specificity of RXR homodimerization
and heterodimerization with RAR and thyroid hormone recep-
tor and subsequent DNA binding (13). Ligand binding to thy-
roid hormone receptor and RAR exposes a region different from
the ninth heptad repeat to promote interactions with RXR (43).
Val-889 precedes by four amino acids the AF2 activation core
region predicted for AR based on sequence similarity among
the family of steroid hormone receptors (44). Unlike other
steroid receptors, however, a transcriptional activation func-
tion in the AR steroid binding domain has remained elusive
(18, 45, 46). It is conceivable that this region contributes to
transcriptional activation through its interaction with the
NH2-terminal region. Val-889 follows by two amino acids a
region in the steroid binding domain implicated in ER dimer-
ization and high affinity DNA binding (9). A preponderance of
indirect evidence implicates, therefore, the region of Val-889
not only in major conformational changes upon androgen bind-
ing that could alter the availability of the steroid binding
pocket but in association with AR dimerization and transcrip-
tional activation. We postulate that one of the underlying
mechanisms in these processes involves the intermolecular
N-C interaction that occurs during androgen-induced AR
dimerization.
Mutations at both residues implicated in the N/C interaction,
Val-889 and Arg-752, cause an 8–12-fold increase in androgen
dissociation rate, whereas dissociation rates of the other mu-
tations were only 3–4-fold increased. This result suggests that
FIG. 8. Influence of the AR NH2-terminal and DNA binding
domain fragment on degradation of the steroid binding domain
fragment. Transient transfections in COS-1 cells were performed us-
ing DEAE-dextran and 4 mg of AR507–919 plus 8 mg of the parent
vector pCMV5 (p5) or 8 mg AR1–660 coding for the NH2-terminal and
DNA binding regions. After 48 h, cells were incubated for 30 min with
100 mCi of 35S-labeled cysteine-methionine as described under “Exper-
imental Procedures” followed by a chase period. AR fragments were
harvested at increasing time intervals, immunoprecipitated using
AR52 anti-peptide antibody, and analyzed on a 9% acrylamide gel
containing SDS (A and B). C, shown are degradation rate data for AR
507–919 1 pCMV5 (p5) in the absence of androgen (M), AR507–919 1
p5 1 100 nM DHT (L), AR507–919 1 AR1–660 in the absence of
androgen (E), and AR507–919 1 AR1–660 1 100 nM DHT (‚). Inten-
sities of the AR507–919 bands shown in A and B were determined on an
LKB laser densitometer and are shown on a semi-log scale.
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very rapid androgen dissociation either promotes or results
from disruption of the N-C interaction. The further increase in
dissociation rate with deletion of the NH2-terminal domain
suggests stabilization of bound androgen by the NH2-terminal
domain. In the case of V889M and R752Q, some degree of
stabilization of bound androgen in the full-length mutants
likely resulted from the high, pharmacological androgen levels
used in the dissociation experiments, concentrations at which
these mutants are transcriptionally active. The NH2-terminal
region not only stabilizes androgen in the steroid binding
pocket but also slows the turnover rate of the steroid binding
domain in the bimolecular N-C interaction with wild-type AR
fragments, both of which parallel characteristics of the full-
length transcriptionally active AR. Whether the rapid andro-
gen dissociation kinetics of V889M and R752Q is an inherent
property of the steroid binding domain or results from the
disrupted N-C interaction is unclear. Both Val-889 and Arg-752
are not likely directly part of the androgen binding pocket but
could influence dissociation and association rates without sig-
nificantly changing the apparent equilibrium binding constant
while also having a role in the N-C interaction. Based on
sequence similarity with the thyroid hormone b receptor, the
crystal structure places Val-889 on the same surface as Arg-
752 across the steroid binding pocket adjacent to a mixed b
sheet region (40). Val-866, on the other hand, not implicated in
the N-C interaction, is on a different surface of the steroid
binding domain.
None of the AR mutations introduced into the full-length
AR-VP16 fusion protein significantly alter the N-C interaction
with the wild-type GAL4 DNA binding domain-AR steroid
binding domain fusion protein. However, some of the same
mutations introduced into the GALD-H steroid binding domain
fragment eliminate the interaction with full-length AR at phys-
iological androgen concentrations. The failure of full-length
VPAR to interact with V889M-GALD-H or R752Q-GALD-H
except at high androgen concentration, whereas GALD-H in-
teracts with the mutant VPARs, indicates that the AR N-C
interaction is intermolecular and that any resulting conforma-
tion changes do not impose a C-C interaction between the
steroid binding domains. The lack of C-C interactions between
human AR monomers agrees with previous results in the 2-hy-
brid protein interaction assay (18).
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